Linked Data API

Show Search Form

Search Results

867181
registered interest false more like this
date less than 2018-03-19more like thismore than 2018-03-19
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Lumacaftor/ivacaftor more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made for the implications for its policy of new data published by Vertex Pharmaceuticals in February 2018 on the Cystic Fibrosis drug Orkambi. more like this
tabling member constituency York Outer more like this
tabling member printed
Julian Sturdy more like this
uin 133299 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-03-27more like thismore than 2018-03-27
answer text <p>The Government has made no such assessment itself. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of NHS resources. NICE published guidance on the use of Orkambi for the treatment of cystic fibrosis in July 2016 and was not able to recommend it for routine use on the NHS.</p><p> </p><p>NICE has advised that it has not been notified of any new data published in February 2018 related to the use of Orkambi. NICE periodically reviews its technology appraisal guidance to determine whether any new evidence, including new trial data, has emerged that may affect its original recommendations. NICE is next scheduled to review its guidance on the use of Orkambi in July 2019, at which point it will conduct a search for new evidence. NICE’s guidance may be reviewed before the expected review date if significant new evidence emerges that is likely to change the recommendations. The company or any other stakeholder can alert NICE to new evidence in line with its established processes to request an early review.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine remove filter
grouped question UIN 133296 more like this
question first answered
less than 2018-03-27T11:54:59.16Zmore like thismore than 2018-03-27T11:54:59.16Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4079
label Biography information for Julian Sturdy more like this